ロード中...
Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel®, induced high-level neutralizing antibodies and protective immunity with minimal immunopathol...
保存先:
| 出版年: | Hum Vaccin Immunother |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7482854/ https://ncbi.nlm.nih.gov/pubmed/32298218 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1740560 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|